Cipaglucosidase alfa (Pombiliti)
Enzyme replacement therapy (lysosomal enzyme)
Cipaglucosidase alfa (Pombiliti)
Forms and strengths
Form: TabletStrength: 105 mg/vial (reconstituted to 15 mg/mL)
References
Indication
- Cipaglucosidase alfa, given together with miglustat capsules, is indicated for the treatment of late-onset Pompe disease (acid alpha-glucosidase deficiency) in adults weighing at least 40 kg.
- It is not authorized for use as a stand-alone therapy; it must always be paired with miglustat capsules.
Pregnancy
Contraindicated in pregnancy. Confirm pregnancy status and discuss alternative therapy with the prescriber before dispensing.
- Cipaglucosidase alfa in combination with miglustat is contraindicated during pregnancy, since animal studies showed the combination may cause harm to the developing embryo or fetus and there are no clinical data in pregnant women.
Breastfeeding
- Breastfeeding is not recommended during treatment, since it is not known whether cipaglucosidase alfa passes into human breast milk and animal studies showed it is excreted into milk.
Geriatrics
- Limited clinical experience in patients 65 years and older suggests no meaningful difference in safety or effectiveness compared with younger adults, and no dose adjustment is required based on age alone.
Pediatrics
- Cipaglucosidase alfa is not authorized for pediatric use, since no data are available in patients under 18 years of age.
Dosage & Administration
- Cipaglucosidase alfa must always be given together with 65 mg miglustat capsules; it is never used alone.
- The recommended dose is 20 mg/kg body weight, given as an intravenous infusion every other week.
- The infusion should begin about 1 hour after taking the miglustat capsules, and no later than 3 hours after, if the infusion is delayed.
- The infusion is given over approximately 4 hours: an initial rate of no more than 1 mg/kg/hr for the first 30 minutes, increased by 2 mg/kg/hr every 30 minutes as tolerated, up to a maximum of 7 mg/kg/hr.
- Premedication with an antihistamine, antipyretic, and/or corticosteroid may be given before the infusion to help prevent infusion-associated reactions.
- Patients switching from another enzyme replacement therapy can start cipaglucosidase alfa-miglustat treatment at their next scheduled dosing time, generally about 2 weeks after their last prior infusion.
- No specific dose adjustment has been established for kidney or liver impairment, since these populations have not been studied.
- No dose adjustment is required for patients 65 years of age or older.
- If the miglustat dose is missed, the cipaglucosidase alfa infusion should not be started; both medicines should instead be rescheduled together at least 24 hours later.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- There is no reported experience with overdose of cipaglucosidase alfa or its companion medication, miglustat.
- If overdose is suspected, supportive medical care and close monitoring of the patient's clinical status are recommended.
Common side effects
- Headache is common.
- Diarrhea is common.
- Fatigue is common.
- Nausea may occur.
- Abdominal pain may occur.
- Abdominal bloating (distension) may occur.
- Fever may occur.
- Chills may occur.
- Dizziness may occur.
- Altered sense of taste (dysgeusia) may occur.
- Muscle spasms may occur.
- Mild flushing of the skin may occur.
- A faster than normal heartbeat (tachycardia) may occur.
- Joint pain (arthralgia) may occur.
- General weakness (asthenia) may occur.
- Constipation or indigestion may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Life-threatening hypersensitivity reactions, including anaphylaxis, have occurred with cipaglucosidase alfa treatment.
- Severe infusion-associated reactions can include swelling of the throat (pharyngeal edema).
- Severe infusion-associated reactions can include hives (urticaria).
- Severe infusion-associated reactions can include difficulty breathing (dyspnea) or wheezing.
- Severe infusion-associated reactions can include a sudden drop in blood pressure (hypotension).
- Severe infusion-associated reactions can include marked flushing.
- Immune complex-related reactions, including severe skin reactions and kidney (nephrotic) syndrome, have been reported with related enzyme replacement therapies and cannot be ruled out as a class effect.
- Patients with underlying heart or lung compromise may be at risk of serious worsening of their cardiac or respiratory status from fluid volume during the infusion.
- Near-fainting (presyncope) may occur during or after an infusion.
- Seek urgent medical attention for facial or throat swelling, widespread hives, wheezing, chest tightness, or fainting during or shortly after an infusion.
Use with caution
- Use with caution and ensure cardiopulmonary resuscitation equipment and appropriate medical support are available during every infusion.
- Use with caution in patients with a history of reactions to a previous enzyme replacement therapy; continue any premedication that worked well with the prior therapy.
- Use with caution in patients with underlying respiratory illness or compromised heart or lung function, given the risk of fluid-overload complications during infusion.
- Use with caution when considering home infusion; it is only appropriate for patients who have tolerated infusions well for several months and have the necessary support and monitoring in place.
- Use with caution in patients who develop high levels of antidrug antibodies, given the potential for immune complex-related reactions.
- Caution is advised when driving or operating machinery after an infusion, since dizziness, low blood pressure, and drowsiness have been reported.
- Confirm the pregnancy status of women of reproductive potential before starting treatment, and advise effective contraception during treatment and for 4 weeks after the last dose.
- Use with caution in patients with advanced Pompe disease and compromised cardiac or respiratory function, who may be at higher risk of severe complications from an infusion reaction.
Contraindications
- Contraindicated in patients with a history of life-threatening hypersensitivity or infusion-associated reaction to cipaglucosidase alfa where a repeat attempt at treatment was unsuccessful.
- Contraindicated in patients who are hypersensitive to miglustat or to any ingredient in the miglustat capsule, since cipaglucosidase alfa cannot be used without it.
- Contraindicated in women who are or may become pregnant.
Drug interactions
- No formal drug-drug interaction studies have been conducted with cipaglucosidase alfa.
- Interactions with herbal products have not been established.
- Interactions with laboratory tests have not been established.
- Because cipaglucosidase alfa must always be used together with miglustat, the interaction profile of miglustat itself, a small molecule with its own interaction potential, should also be reviewed before starting treatment.
Food interactions
- No food interactions have been established for cipaglucosidase alfa itself, since it is given intravenously.
- The companion miglustat capsule has its own specific food-timing and fasting requirements that must be followed for treatment to work as intended.
Time of administration
- Given as an intravenous infusion every other week, timed to start about 1 hour after the miglustat dose, and no later than 3 hours after.
- Each infusion takes approximately 4 hours and is given by a healthcare professional or trained caregiver, in a hospital, clinic, or approved home setting.
Storage
- Store unopened vials under refrigeration at 2°C to 8°C; do not freeze; protect from light.
- Once reconstituted with sterile water, the vial may be stored refrigerated for up to 24 hours.
- Once diluted for infusion, the solution may be stored refrigerated for up to 24 hours, followed by up to 6 hours at room temperature; do not freeze or shake it.
Patient take-away
- Pombiliti (cipaglucosidase alfa) is an every-other-week infusion for late-onset Pompe disease that must always be taken together with your miglustat capsules; infusion reactions and allergic reactions are possible, so infusions are closely monitored, and you should report any swelling, rash, breathing difficulty, or fainting right away.